4.6 Article

Blocking P2X7-Mediated Macrophage Polarization Overcomes Treatment Resistance in Lung Cancer

期刊

CANCER IMMUNOLOGY RESEARCH
卷 8, 期 11, 页码 1426-1439

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-20-0123

关键词

-

资金

  1. National Key R&D Program of China [2018YFA0507001]
  2. National Natural Science Foundation of China [81672811, 31770969, 81871250, 81902892]
  3. Shanghai Super Postdoctoral Incentive Program
  4. China Postdoctoral Science Foundation [2018M640364]
  5. Shanghai Sailing Program [19YF1414400]
  6. Innovation Program of Shanghai Municipal Education Commission [2017-01-07-00-05-E00011]

向作者/读者索取更多资源

P2X7, a crucial sensor of extracellular ATP, is widely distributed in different immune cells as a potent stimulant of inflammation and immunity. P2X7 is also highly expressed in immunosuppressive cells such as tumor-associated macrophages (TAM) and even tumor cells. However, the function and potential applications of P2X7-mediated immunosuppressive responses in the tumor microenvironment remain unclear. Here, we demonstrated that P2X7 was highly expressed in TAMs and that P2X7 deficiency impaired the M2-like polarization of TAMs via downregulation of STAT6 and IRF4 phosphorylation both in vivo and in vitro. P2X7 deficiency restricted the progression of urethane-induced lung carcinogenesis and Lewis lung cancer by decreasing tumor cell proliferation and angiogenesis, promoting T-cell mobilization, and reversing M2-like TAM polarization. Thus, deletion or blockade of P2X7 was therapeutic for lung cancer. Furthermore, resistance to both immunotherapy (anti-PD-1 antibody) and chemotherapy (cisplatin) was overcome by coadministration of the P2X7 inhibitors O-ATP, A-438079 hydrochloride, and A-740003. Therefore, our data revealed a vital role of P2X7 in tumor formation through regulating TAM polarization, suggesting the therapeutic potential of P2X7 blockade in patients with lung cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据